Viking Therapeutics, Cava, Rubrik, Forward Air, and Bristol Myers Squibb have all shown varied performances in the stock market this year. While some like Cava and Rubrik have seen spikes and dips due to market sentiments towards enterprise software, others like Forward Air are benefiting from industry consolidation. However, it is Bristol Myers Squibb that stands out with its steady performance and potential for long-term growth, despite concerns about the time it will take to see results. Investors are advised to consider the unique factors impacting each company's stock performance before making any decisions. For detailed insights on investing strategies, download Jim Cramer's Guide to Investing for free.